evolocumab

5 Big FDA Decisions Expected in August
5 Big FDA Decisions Expected in August
24/7 Wall St
FDA
Exelixis
vemurafenib
aripiprazole lauroxil
Alkermes
evolocumab
Amgen
Bristol-Myers Squibb
Opdivo
Clovis Oncology
rociletinib
Flag link:
More Preliminary Signs That The New Cholesterol Drugs May Improve Outcomes
More Preliminary Signs That The New Cholesterol Drugs May Improve Outcomes
Forbes
Amgen
Sanofi
Regeneron
PCSK9 inhibitors
alirocumab
evolocumab
Flag link:
11 promising drugs poised to be the next billion-dollar blockbusters
11 promising drugs poised to be the next billion-dollar blockbusters
Yahoo/Business Insider
Opdivo
Praluent
LCZ696
lumacaftor
Viekira Pak
evolocumab
Gardasil 9
brexpiprazole
Toujeo
Cosentyx
Bristol-Myers Squibb
Regeneron
Sanofi
Novartis
Pfizer
AbbVie
Amge
Astellas
Merck
Otsuka
Lundbeck
Vertex Pharmaceuticals
Flag link:
Why 2015 is the year of the biopharma blockbuster—with charts
Why 2015 is the year of the biopharma blockbuster—with charts
BioPharma Dive
biotech
Opdivo
Praluent
LCZ696
Ibrance
Viekira Pak
evolocumab
Gardasil 9
Bristol-Myers Squibb
Regeneron
Sanofi
Novartis
Pfizer
Vertex Pharmaceuticals
Merck
Amgen
AbbVie
Astellas
Flag link:
Amgen, Regeneron Stocks Go Up as Drugs Bring Cholesterol Down
Amgen, Regeneron Stocks Go Up as Drugs Bring Cholesterol Down
Forbes
Amgen
Regeneron
PCSK9 inhibitors
alirocumab
evolocumab
Flag link:
3 Leading Biotech Stocks Releasing Potential Catalyst Data This Week
3 Leading Biotech Stocks Releasing Potential Catalyst Data This Week
24/7 Wall St
Amgen
evolocumab
Biogen Idec
BIIB037
OCA
obeticholic acid
Intercept Pharmaceuticals
Flag link:
New Cholesterol Drugs: Highly Effective But Important Questions Remain
New Cholesterol Drugs: Highly Effective But Important Questions Remain
Forbes
PCSK9 inhibitors
alirocumab
evolocumab
Amgen
Sanofi
Regeneron
Flag link:
Amgen scores a victory for PCSK9, halving cardio risks after one year
Amgen scores a victory for PCSK9, halving cardio risks after one year
Fierce Biotech
Amgen
PCSK9 inhibitors
evolocumab
Flag link:
Could Amgen's Next Drug Be Worth $100 Billion?
Could Amgen's Next Drug Be Worth $100 Billion?
Investopedia
Amgen
evolocumab
Flag link:
Is This Amgen's Next Big Thing?
Is This Amgen's Next Big Thing?
Investopedia
Amgen
evolocumab
biosimilars
Flag link:
Sanofi and Regeneron Gain Edge on Amgen in Cholesterol Drug Race
Sanofi and Regeneron Gain Edge on Amgen in Cholesterol Drug Race
Bloomberg
Sanofi
Regeneron
Amgen
alirocumab
evolocumab
PCSK9 inhibitors
Flag link:
FirstWord Lists – The drugs that will shape 2015
FirstWord Lists – The drugs that will shape 2015
First Word Pharma
Harvoni
Viekira Pak
Gilead Sciences
AbbVie
alirocumab
evolocumab
Amgen
Regeneron
Sanofi
Opdivo
Keytruda
Merck
Bristol-Myers Squibb
Novartis
CTL019
Zarxio
Pfizer
palbociclib
Saxenda
Trulicity
Afrezza
MannKind
Eli Lilly
Novo Nordisk
LCZ696
Toujeo
Breo Ellipta
GED-0301
Celgene
BiogenIdec
Flag link:
5 Potential Blockbuster Drugs Set To Launch In 2015
5 Potential Blockbuster Drugs Set To Launch In 2015
Investors.com
Amgen
Regeneron
evolocumab
alirocumab
Alexion
asfotase alfa
Novartis
LCZ696
Pfizer
palbociclib
Flag link:
FDA Accepts Amgen's Biologics License Application For LDL Cholesterol-Lowering Medication Evolocumab
FDA Accepts Amgen's Biologics License Application For LDL Cholesterol-Lowering Medication Evolocumab
Yahoo
FDA
Amgen
evolocumab
Flag link:
Amgen Files Lawsuit Against Sanofi And Regeneron For Patent Infringement
Amgen Files Lawsuit Against Sanofi And Regeneron For Patent Infringement
Yahoo
Amgen
Sanofi
Regeneron
patents
alirocumab
monoclonal antibodies
evolocumab
Flag link:
Amgen: Why Its New Drug Application is a Big Deal
Amgen: Why Its New Drug Application is a Big Deal
Barron's
Amgen
evolocumab
PCSK9 inhibitors
Flag link:
Amgen submits U.S. application to sell cholesterol-fighting drug
Amgen submits U.S. application to sell cholesterol-fighting drug
Yahoo/Reuters
Amgen
PCSK9 inhibitors
evolocumab
Flag link:
As race to market intensifies, how expectant are cardiologists for PCSK9 inhibitor class?
As race to market intensifies, how expectant are cardiologists for PCSK9 inhibitor class?
First Word Pharma
cardiologists
physicians
PCSK9 inhibitors
Sanofi
Regeneron
Amgen
evolocumab
alirocumab
Flag link:
FirstWord Lists: Pharma's biggest pipeline drugs
FirstWord Lists: Pharma's biggest pipeline drugs
First Word Pharma
pipelines
nivolumab
Pembrolizumab
evolocumab
palbociclib
cancer
breast cancer
Pfizer
Bristol-Myers Squibb
Merck
Amgen
Flag link:
3 Undervalued Amgen Growth Opportunities to Watch
3 Undervalued Amgen Growth Opportunities to Watch
Motley Fool
Amgen
evolocumab
Kyprolis
brodalumab
AMG-334
Flag link:

Pages